Can-Fite Biopharma LTD. (CANF) SEC Filings — 2024
36 SEC filings for Can-Fite Biopharma LTD. (CANF) in 2024.
Filings
- ASCO Recognizes Can-Fite's Namodenoson Liver Protection — 6-K · Dec 30, 2024
- Can-Fite BioPharma Files 6-K, Incorporates Press Release — 6-K · Dec 4, 2024
- Can-Fite Biopharma LTD. SC 13G/A Filing — SC 13G/A · Nov 14, 2024
- Can-Fite BioPharma Files 6-K, Incorporates Press Release — 6-K · Nov 12, 2024
- Can-Fite BioPharma's Namodenoson Drug Gets Australian Patent Allowance — 6-K · Nov 4, 2024
- Can-Fite BioPharma Files 6-K, Incorporates Press Release — 6-K · Oct 18, 2024
- Can-Fite BioPharma Ltd. Files 6-K, Incorporates Press Release — 6-K · Oct 9, 2024
- Can-Fite BioPharma Licenses Piclidenoson, Projects $325M Income — 6-K · Sep 24, 2024
- Can-Fite BioPharma Files 6-K, Incorporates Press Release — 6-K · Sep 16, 2024
- Can-Fite BioPharma Files Form 6-K — 6-K · Aug 30, 2024
- Can-Fite BioPharma Ltd. Files 6-K for June 30, 2024 — 6-K · Aug 29, 2024
- Can-Fite BioPharma Files 6-K, Incorporates Inducement Letter — 6-K · Aug 12, 2024
- Can-Fite BioPharma Raises $10.5M in Public Offering — 6-K · Aug 9, 2024
- Can-Fite BioPharma Updates Namodenoson Patent Status — 6-K · Jul 29, 2024
- Can-Fite BioPharma Files 6-K, Incorporates Press Release — 6-K · Jul 11, 2024
- Can-Fite BioPharma Holds Annual Shareholder Meeting — 6-K · Jul 3, 2024
- Can-Fite BioPharma Reports Namodenoson Success in Liver Cirrhosis — 6-K · Jul 1, 2024
- Can-Fite BioPharma: Osteoarthritis Study in Dogs Shows Positive Results — 6-K · Jun 28, 2024
- Can-Fite BioPharma Annual Meeting Adjourned Due to Lack of Quorum — 6-K · Jun 26, 2024
- Can-Fite BioPharma: Namodenoson Shows Liver Cancer & Protective Effects — 6-K · Jun 24, 2024
- Can-Fite BioPharma Closes $1.5M Public Offering — 6-K · Jun 10, 2024
- Can-Fite BioPharma Updates Liver Cancer Phase 3 Study — 6-K · Jun 5, 2024
- Can-Fite Drugs Show Therapeutic Effects on Heart Diseases in Review — 6-K · May 29, 2024
- Can-Fite BioPharma Files Form 6-K for May 2024 — 6-K · May 22, 2024
- Can-Fite BioPharma Conference Boosts Liver Cancer Study Enrollment — 6-K · May 13, 2024
- Can-Fite BioPharma Closes $1.7M Public Offering — 6-K · May 9, 2024
- Can-Fite BioPharma Files 6-K, Incorporates Press Release — 6-K · May 6, 2024
- Can-Fite BioPharma's Namodenoson Shows Long-Term Cancer Response — 6-K · Apr 25, 2024
- Can-Fite BioPharma's Namodenoson Featured in Liver Cancer Study — 6-K · Apr 15, 2024
- Can-Fite BioPharma's Piclidenoson Shows Promise in Psoriasis Study — 6-K · Apr 3, 2024
- Can-Fite BioPharma Ltd. Files 2023 Annual Report on Form 20-F — 20-F · Mar 28, 2024
- Can-Fite BioPharma to Discuss Namodenoson Cancer Data at Bio Europe — 6-K · Mar 11, 2024
- Can-Fite BioPharma Updates SEC Filings with Press Release Reference — 6-K · Feb 28, 2024
- Can-Fite Biopharma LTD. SC 13G Filing — SC 13G · Feb 14, 2024
- Can-Fite Expands Ewopharma Deal to Include Pancreatic Cancer — 6-K · Jan 30, 2024
- Can-Fite's Piclidenoson Phase III Psoriasis Data Published in Top Journal — 6-K · Jan 29, 2024